-
1
-
-
0031601658
-
National health spending trends in 1996
-
Levit K, Lazenby H, Braden B, and the National Health Accounts Team. National health spending trends in 1996. Health Aff 1998: 17:35-51.
-
(1998)
Health Aff
, vol.17
, pp. 35-51
-
-
Levit, K.1
Lazenby, H.2
Braden, B.3
-
2
-
-
2642685027
-
Notes on current labor statistics: Price data
-
Washington, DC; US Government Printing Office
-
US Department of Labor. Notes on current labor statistics: price data. Monthly Labor Review 120. No. 1. Washington, DC; US Government Printing Office. 1997.
-
(1997)
Monthly Labor Review 120
, vol.1
-
-
-
3
-
-
0031910689
-
Projecting future drug expenditures - 1998
-
Mehl B, Santell J. Projecting future drug expenditures - 1998. Am J Health Syst Pharm 1998;55:127-135.
-
(1998)
Am J Health Syst Pharm
, vol.55
, pp. 127-135
-
-
Mehl, B.1
Santell, J.2
-
4
-
-
0002377305
-
Some HMOs now put doctors on a budget for prescription drugs
-
May 22
-
Johannes L. Some HMOs now put doctors on a budget for prescription drugs. Wall Street Journal. May 22, 1997:A1, A6.
-
(1997)
Wall Street Journal
-
-
Johannes, L.1
-
5
-
-
1642506056
-
Worldwide ophthalmic drug sales projected to reach $3.18 billion in 1996 vs $3 billion in 1995
-
Philadelphia: Dorland's Biomedical
-
Worldwide ophthalmic drug sales projected to reach $3.18 billion in 1996 vs $3 billion in 1995. Medical & Health Care Marketplace Guide. 12th ed. Philadelphia: Dorland's Biomedical, 1996:169.
-
(1996)
Medical & Health Care Marketplace Guide. 12th Ed.
, pp. 169
-
-
-
6
-
-
1642506054
-
Pharmacia & Upjohn Inc's Xalatan ophthalmic product generated sales of $65 million in 1996; to reach S115 million by 1997
-
Pharmacia & Upjohn Inc's Xalatan ophthalmic product generated sales of $65 million in 1996; to reach S115 million by 1997. R&D Directions 1997;2:41.
-
(1997)
R&D Directions
, vol.2
, pp. 41
-
-
-
7
-
-
1642465301
-
Selective alpha-2 agonist for treatment of glaucoma aimed at market estimated at $1 billion
-
Selective alpha-2 agonist for treatment of glaucoma aimed at market estimated at $1 billion. PharmaBusiness 1998;20;82.
-
(1998)
PharmaBusiness
, vol.20
, pp. 82
-
-
-
8
-
-
1642546856
-
The worldwide glaucoma market is worth $1 billion and may rise 7.5% per year
-
The worldwide glaucoma market is worth $1 billion and may rise 7.5% per year. PharmaBusiness 1997;16:77.
-
(1997)
PharmaBusiness
, vol.16
, pp. 77
-
-
-
9
-
-
0000832785
-
Quantitative and cost evaluation of three antiglaucoma beta-blocker agents: Timoptic-XE versus two generic levobunolol products
-
Hartenbaum D, et al. Quantitative and cost evaluation of three antiglaucoma beta-blocker agents: Timoptic-XE versus two generic levobunolol products. Am J Managed Care 1996;2:157-162.
-
(1996)
Am J Managed Care
, vol.2
, pp. 157-162
-
-
Hartenbaum, D.1
-
10
-
-
0024579844
-
Comparison of timolol maleate and levobunolol: Doses and volume per bottle
-
Schwartz J. Christensen R, Lee D. Comparison of timolol maleate and levobunolol: doses and volume per bottle. Arch Ophthalmol 1989;107:17-18.
-
(1989)
Arch Ophthalmol
, vol.107
, pp. 17-18
-
-
Schwartz, J.1
Christensen, R.2
Lee, D.3
-
11
-
-
0022512760
-
Drop size of commercial glaucoma medications
-
Lederer C, Harold R. Drop size of commercial glaucoma medications. Am J Ophthalmol 1986;101:691-694.
-
(1986)
Am J Ophthalmol
, vol.101
, pp. 691-694
-
-
Lederer, C.1
Harold, R.2
-
12
-
-
0030803039
-
Daily cost of beta-adrenergic blocker therapy
-
Stewart WC, Sine C, Kate E, Minno GE, Hunt HH. Daily cost of beta-adrenergic blocker therapy. Arch Ophthalmol 1997;115:853-856.
-
(1997)
Arch Ophthalmol
, vol.115
, pp. 853-856
-
-
Stewart, W.C.1
Sine, C.2
Kate, E.3
Minno, G.E.4
Hunt, H.H.5
-
13
-
-
0026728953
-
Cost of beta-adrenergic receptor blocking agents for ocular hypertension
-
Schreider E, Ball S. Cost of beta-adrenergic receptor blocking agents for ocular hypertension. Arch Ophthalmol 1992;110:654-657.
-
(1992)
Arch Ophthalmol
, vol.110
, pp. 654-657
-
-
Schreider, E.1
Ball, S.2
-
14
-
-
0032005245
-
Costs of glaucoma medications
-
Fiscella R. Costs of glaucoma medications. Am J Health Syst Pharm 1998;55:272-275.
-
(1998)
Am J Health Syst Pharm
, vol.55
, pp. 272-275
-
-
Fiscella, R.1
|